trending Market Intelligence /marketintelligence/en/news-insights/trending/YycYngmyxX1_QMLpWOSm0g2 content esgSubNav
In This List

US FDA approves Novo Nordisk's drug for hemophilia B

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA approves Novo Nordisk's drug for hemophilia B

The U.S. FDA approved the biologics license application for Novo Nordisk A/S' REBINYN, a drug to treat adults and children with hemophilia B, a blood clotting disorder.

Novo Nordisk plans to launch the drug in the U.S. during the first half of 2018.